{"id":44610,"date":"2022-06-02T13:01:11","date_gmt":"2022-06-02T11:01:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/"},"modified":"2022-06-02T13:01:11","modified_gmt":"2022-06-02T11:01:11","slug":"silence-therapeutics-to-present-at-jefferies-healthcare-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/","title":{"rendered":"Silence Therapeutics to Present at Jefferies Healthcare Conference"},"content":{"rendered":"<div>\n<p>LONDON&#8211;(BUSINESS WIRE)&#8211;Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9<sup>th <\/sup>at 10:00 a.m. EDT \/ 2:00 p.m. GMT.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220602005054\/en\/1471857\/5\/Silence-Logo-FINAL-rgb.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220602005054\/en\/1471857\/21\/Silence-Logo-FINAL-rgb.jpg\"><\/a><\/p>\n<p>\nA live webcast of the presentation can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company\u2019s website following the conference.\n<\/p>\n<p>\n<b>About Silence Therapeutics<br \/>\n<br \/><\/b>Silence Therapeutics is developing a new generation of medicines by harnessing the body&#8217;s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence&#8217;s proprietary mRNAi GOLD\u2122 platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence&#8217;s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DseWLk0Tijvb87pYYtHlfJBSxU-O0-uhbTanKn5RhA2rNJ_BGh5GwtTTFOolm5n2IgC_sZlfXwUjJf1q1KZQGqwMF9rpkGI9IXJVi3CKfXBhC7d9RDrI9bKFnvBa_D7yENo8TBNOrH81g_BaE5LBZTg%3D%3D&amp;esheet=52735641&amp;newsitemid=20220602005054&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.silence-therapeutics.com%2F&amp;index=1&amp;md5=909af8281c41d8db637185a7d5f32e38\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.silence-therapeutics.com\/<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Silence Therapeutics plc<\/b><br \/>Gem Hopkins, Head of IR and Corporate Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x69;&#114;&#64;&#115;&#105;&#108;&#101;&#110;ce-t&#x68;&#x65;&#x72;&#x61;&#x70;&#x65;&#x75;&#x74;&#x69;&#99;&#115;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x72;&#64;s&#x69;&#x6c;&#x65;&#110;c&#x65;&#x2d;&#x74;&#104;e&#x72;&#x61;&#x70;&#101;u&#x74;&#x69;&#x63;&#115;&#46;&#x63;&#x6f;&#x6d;<\/a><br \/>Tel: +1 (646) 637-3208\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON&#8211;(BUSINESS WIRE)&#8211;Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9th at 10:00 a.m. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44610","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silence Therapeutics to Present at Jefferies Healthcare Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silence Therapeutics to Present at Jefferies Healthcare Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON&#8211;(BUSINESS WIRE)&#8211;Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9th at 10:00 a.m. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-02T11:01:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220602005054\/en\/1471857\/21\/Silence-Logo-FINAL-rgb.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Silence Therapeutics to Present at Jefferies Healthcare Conference\",\"datePublished\":\"2022-06-02T11:01:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/\"},\"wordCount\":264,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005054\\\/en\\\/1471857\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/\",\"name\":\"Silence Therapeutics to Present at Jefferies Healthcare Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005054\\\/en\\\/1471857\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\",\"datePublished\":\"2022-06-02T11:01:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005054\\\/en\\\/1471857\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005054\\\/en\\\/1471857\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silence Therapeutics to Present at Jefferies Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silence Therapeutics to Present at Jefferies Healthcare Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Silence Therapeutics to Present at Jefferies Healthcare Conference - Pharma Trend","og_description":"LONDON&#8211;(BUSINESS WIRE)&#8211;Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9th at 10:00 a.m. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-02T11:01:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220602005054\/en\/1471857\/21\/Silence-Logo-FINAL-rgb.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Silence Therapeutics to Present at Jefferies Healthcare Conference","datePublished":"2022-06-02T11:01:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/"},"wordCount":264,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005054\/en\/1471857\/21\/Silence-Logo-FINAL-rgb.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/","url":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/","name":"Silence Therapeutics to Present at Jefferies Healthcare Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005054\/en\/1471857\/21\/Silence-Logo-FINAL-rgb.jpg","datePublished":"2022-06-02T11:01:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220602005054\/en\/1471857\/21\/Silence-Logo-FINAL-rgb.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220602005054\/en\/1471857\/21\/Silence-Logo-FINAL-rgb.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-jefferies-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Silence Therapeutics to Present at Jefferies Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44610"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44610\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}